Cerevance Parkinson’s drug shortens 'off time' in Ph. 3, paving path to FDA

Phase 3positivesolengeprasPositive

AI Analysis

Summary

Cerevance's solengepras demonstrated positive Phase 3 results in reducing 'off time' periods in Parkinson's disease patients at a high dose, advancing the program toward FDA submission. The drug is being developed by Takeda's spinout company Cerevance.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

High dose of solengepras showed efficacy in shortening 'off time' periods characterized by involuntary movements and sleepiness in Parkinson's disease patients

Importance:7/10

Sentiment:

0.75

Parkinson's diseasePhase 3 datasolengeprasTakeda spinoutFDA pathway

Related Companies

$TAK

Read the original article

Published by BioSpace on October 7, 2026 2:44 PM

Read Original